$ROIV
Roivant Sciences Ltd. Stock $roiv

$roiv Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000119312522220561 Filed on August 15, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$12.53M	$4.319M	$9.223M
YoY Change	-10.4%	-44.16%	-39.11%
Cost Of Revenue	$3.641M	$1.726M	$459.0K
YoY Change	-42.94%	132.61%	-3.97%
Gross Profit	$8.892M	$2.593M	$8.764M
YoY Change	16.91%	-62.92%	-40.25%
Gross Profit Margin	70.95%	60.04%	95.02%
Selling, General & Admin	$157.7M	$149.1M	$139.0M
YoY Change	-63.99%	80.14%	71.26%
% of Gross Profit	1773.09%	5749.02%	1585.73%
Research & Development	$132.0M	$135.8M	$136.6M
YoY Change	-48.09%	73.0%	-71.2%
% of Gross Profit	1484.42%	5238.33%	1558.58%
Depreciation & Amortization	$7.753M	$2.678M
YoY Change
% of Gross Profit	87.19%	103.28%
Operating Expenses	$293.3M	$286.6M	$275.6M
YoY Change	-57.62%	76.8%	-50.39%
Operating Profit	-$280.8M	-$282.3M	-$266.8M
YoY Change	-58.98%	82.86%	-50.67%
Interest Expense	-$57.34M	$2.612M	-$74.21M
YoY Change	-112.08%	3.94%	503.81%
% of Operating Profit
Other Income/Expense, Net	-$8.615M	-$1.716M	$44.50M
YoY Change	-43.87%	-1380.6%	-542.43%
Pretax Income	-$313.8M	-$349.8M	-$291.5M
YoY Change	39.3%	246.37%	-48.24%
Income Tax	$2.165M	$3.999M	-$163.0K
% Of Pretax Income
Net Earnings	-$291.6M	-$331.8M	-$270.1M
YoY Change	29.23%	303.74%	-47.0%
Net Earnings / Revenue	-2326.58%	-7682.54%	-2928.14%
Basic Earnings Per Share	-$0.42	-$0.48
Diluted Earnings Per Share	-$0.42	-$0.48	-$390.1K
COMMON SHARES
Basic Shares Outstanding	703.6M	695.9M
Diluted Shares Outstanding	699.9M	695.9M

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.599B	$1.942B	$2.060B
YoY Change	-35.97%	-2.73%	141023.29%
Cash & Equivalents	$1.599B	$1.942B	$2.060B
Short-Term Investments
Other Short-Term Assets	$111.8M	$93.27M	$82.22M
YoY Change	142.58%	68.16%	34158.33%
Inventory			$0.00
Prepaid Expenses	$70.30M		$53.37M
Receivables	$25.04M
Other Receivables	$2.331M
Total Short-Term Assets	$1.715B	$2.039B	$2.147B
YoY Change	-32.9%	-0.88%	126166.06%
LONG-TERM ASSETS
Property, Plant & Equipment	$39.17M	$31.69M	$25.91M
YoY Change	-51.1%	-60.74%
Goodwill
YoY Change
Intangibles	$140.3M	$145.4M	$0.00
YoY Change
Long-Term Investments	$246.6M	$301.3M	$325.8M
YoY Change	-43.54%	7.25%	-20.68%
Other Assets	$11.87M	$12.82M	$16.09M
YoY Change	-60.77%	-63.84%
Total Long-Term Assets	$500.7M	$561.0M	$438.6M
YoY Change	-8.49%	41.27%	6.77%
TOTAL ASSETS
Total Short-Term Assets	$1.715B	$2.039B	$2.147B
Total Long-Term Assets	$500.7M	$561.0M	$438.6M
Total Assets	$2.216B	$2.600B	$2.585B
YoY Change	-28.6%	5.94%	526.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$41.36M	$161.3M	$34.58M
YoY Change	-46.4%	974.36%	31339.09%
Accrued Expenses	$128.8M	$109.4M	$127.5M
YoY Change	11.4%	27.39%	591.22%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$33.30M	$0.00
YoY Change
Long-Term Debt Due	$35.75M	$33.30M	$0.00
YoY Change
Total Short-Term Liabilities	$230.7M	$328.9M	$184.4M
YoY Change	-23.96%	57.26%	892.29%
LONG-TERM LIABILITIES
Long-Term Debt	$376.1M	$383.7M	$210.0M
YoY Change	88.15%	105.91%
Other Long-Term Liabilities	$9.104M	$8.159M	$8.183M
YoY Change	-93.88%	-89.72%	-68.7%
Total Long-Term Liabilities	$9.104M	$8.159M	$8.183M
YoY Change	-97.39%	-96.93%	-68.7%
TOTAL LIABILITIES
Total Short-Term Liabilities	$230.7M	$328.9M	$184.4M
Total Long-Term Liabilities	$9.104M	$8.159M	$8.183M
Total Liabilities	$701.4M	$822.5M	$523.7M
YoY Change	-34.14%	12.43%	1071.05%
SHAREHOLDERS EQUITY
Retained Earnings	-$3.387B	-$3.100B	-$2.764B
YoY Change	53.32%		44.06%
Common Stock	$0.00	$0.00	$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.161B	$1.384B	$1.657B
YoY Change
Total Liabilities & Shareholders Equity	$2.216B	$2.600B	$2.585B
YoY Change	-28.6%	5.94%	526.71%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	-$291.6M	-$331.8M	-$270.1M
YoY Change	29.23%	303.74%	-47.0%
Depreciation, Depletion And Amortization	$7.753M	$2.678M
YoY Change
Cash From Operating Activities	-$189.6M	-$252.1M	-$147.5M
YoY Change	57.24%	78.57%	-73.29%
INVESTING ACTIVITIES
Capital Expenditures	-$3.101M	$7.459M	-$6.263M
YoY Change	12.31%	218.9%	7.87%
Acquisitions
YoY Change
Other Investing Activities	-$143.8M	$0.00	$561.0K
YoY Change	-144.9%		-102.17%
Cash From Investing Activities	-$146.9M	-$7.459M	-$5.702M
YoY Change	-146.27%	218.9%	-82.01%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-7.341M	142.0M	1.070M
YoY Change	-102.42%	1290.56%	-99.77%
NET CHANGE
Cash From Operating Activities	-189.6M	-252.1M	-147.5M
Cash From Investing Activities	-146.9M	-7.459M	-5.702M
Cash From Financing Activities	-7.341M	142.0M	1.070M
Net Change In Cash	-343.8M	-117.6M	-152.1M
YoY Change	-168.66%	-11.8%	19.22%
FREE CASH FLOW
Cash From Operating Activities	-$189.6M	-$252.1M	-$147.5M
Capital Expenditures	-$3.101M	$7.459M	-$6.263M
Free Cash Flow	-$186.5M	-$259.5M	-$141.2M
YoY Change	58.3%	80.85%	-74.15%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2022Q2	dei	Amendment Flag AmendmentFlag	false
CY2022Q2	dei	Entity Central Index Key EntityCentralIndexKey	0001635088
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00000003
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00000003
CY2022Q2	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q2	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
CY2022Q2	dei	Document Type DocumentType	10-Q
CY2022Q2	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q2	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
CY2022Q2	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q2	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q2	dei	Entity File Number EntityFileNumber	001-40782
CY2022Q2	dei	Entity Registrant Name EntityRegistrantName	ROIVANT SCIENCES LTD.
CY2022Q2	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	D0
CY2022Q2	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1173944
CY2022Q2	dei	Entity Address Address Line1 EntityAddressAddressLine1	Suite 1, 3rd Floor
CY2022Q2	dei	Entity Address Address Line2 EntityAddressAddressLine2	11-12 St. James’s Square
CY2022Q2	dei	Entity Address City Or Town EntityAddressCityOrTown	London
CY2022Q2	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	SW1Y 4LB
CY2022Q2	dei	Entity Address Country EntityAddressCountry	GB
CY2022Q2	dei	Country Region CountryRegion	+44
CY2022Q2	dei	City Area Code CityAreaCode	207
CY2022Q2	dei	Local Phone Number LocalPhoneNumber	400 3347
CY2022Q2	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q2	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q2	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022Q2	dei	Entity Small Business EntitySmallBusiness	true
CY2022Q2	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022Q2	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
CY2022Q2	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	703625412
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1942215000
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2060400000
CY2022Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	3953000
CY2022Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	3903000
CY2022Q2	us-gaap	Other Assets Current OtherAssetsCurrent	93274000
CY2022Q1	us-gaap	Other Assets Current OtherAssetsCurrent	82220000
CY2022Q2	us-gaap	Assets Current AssetsCurrent	2039442000
CY2022Q1	us-gaap	Assets Current AssetsCurrent	2146523000
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	31689000
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	25905000
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	59429000
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	61044000
CY2022Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	10301000
CY2022Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	9731000
CY2022Q2	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	301287000
CY2022Q1	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	325834000
CY2022Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	145430000
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	12820000
CY2022Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	16092000
CY2022Q2	us-gaap	Assets Assets	2600398000
CY2022Q1	us-gaap	Assets Assets	2585129000
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	161304000
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	34583000
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	109354000
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	127531000
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	11858000
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	11398000
CY2022Q2	roiv	Long Term Debt Current Fair Value LongTermDebtCurrentFairValue	27300000
CY2022Q2	us-gaap	Short Term Borrowings ShortTermBorrowings	33304000
CY2022Q1	us-gaap	Short Term Borrowings ShortTermBorrowings	0
CY2022Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	9011000
CY2022Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	10147000
CY2022Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	4084000
CY2022Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	708000
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	328915000
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	184367000
CY2022Q2	roiv	Liability Instruments Measured At Fair Value LiabilityInstrumentsMeasuredAtFairValue	28181000
CY2022Q1	roiv	Liability Instruments Measured At Fair Value LiabilityInstrumentsMeasuredAtFairValue	44912000
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	60395000
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	62468000
CY2022Q2	us-gaap	Long Term Debt Fair Value LongTermDebtFairValue	200700000
CY2022Q1	us-gaap	Long Term Debt Fair Value LongTermDebtFairValue	177400000
CY2022Q2	us-gaap	Long Term Debt LongTermDebt	383720000
CY2022Q1	us-gaap	Long Term Debt LongTermDebt	210025000
CY2022Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	13146000
CY2022Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	13740000
CY2022Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	8159000
CY2022Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	8183000
CY2022Q2	us-gaap	Liabilities Liabilities	822516000
CY2022Q1	us-gaap	Liabilities Liabilities	523695000
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q2	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	22491000
CY2022Q1	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	22491000
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	7000000000
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	7000000000
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	701171465
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	701171465
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	694975965
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	694975965
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	0
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	0
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	4474624000
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	4421614000
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-3095533000
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2763724000
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	5020000
CY2022Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-946000
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	1384111000
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	1656944000
CY2022Q2	us-gaap	Minority Interest MinorityInterest	371280000
CY2022Q1	us-gaap	Minority Interest MinorityInterest	381999000
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1755391000
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	2038943000
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2600398000
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2585129000
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4319000
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7735000
CY2022Q2	roiv	Operating Costs OperatingCosts	1726000
CY2021Q2	roiv	Operating Costs OperatingCosts	742000
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	135830000
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	78515000
CY2022Q2	roiv	Acquired In Process Research And Development Expense AcquiredInProcessResearchAndDevelopmentExpense	0
CY2021Q2	roiv	Acquired In Process Research And Development Expense AcquiredInProcessResearchAndDevelopmentExpense	111000
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	149072000
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	82754000
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	286628000
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	162122000
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-282309000
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-154387000
CY2022Q2	us-gaap	Gain Loss On Investments GainLossOnInvestments	-24547000
CY2021Q2	us-gaap	Gain Loss On Investments GainLossOnInvestments	-8619000
CY2022Q2	roiv	Gain Loss On Fair Value Of Debt And Liability Instruments GainLossOnFairValueOfDebtAndLiabilityInstruments	-41213000
CY2021Q2	roiv	Gain Loss On Fair Value Of Debt And Liability Instruments GainLossOnFairValueOfDebtAndLiabilityInstruments	-4585000
CY2022Q2	roiv	Equity Interest Option To Third Party Purchaser Gain On Termination EquityInterestOptionToThirdPartyPurchaserGainOnTermination	0
CY2021Q2	roiv	Equity Interest Option To Third Party Purchaser Gain On Termination EquityInterestOptionToThirdPartyPurchaserGainOnTermination	66472000
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1716000
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	134000
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-349785000
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-100985000
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3999000
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	93000
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-353784000
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-101078000
CY2022Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-21975000
CY2021Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-18895000
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-331809000
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-82183000
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.48
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.48
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	695878859
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	695878859
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	649856203
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	649856203
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-353784000
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-101078000
CY2022Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	5767000
CY2021Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-2439000
CY2022Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	5767000
CY2021Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-2439000
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-348017000
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-103517000
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-22174000
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-18682000
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-325843000
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-84835000
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	2038943000
CY2022Q2	roiv	Stock Optionsexercised And Equityinstruments Vestedandsettled Net Of Tax StockOptionsexercisedAndEquityinstrumentsVestedandsettledNetOfTax	-8329000
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	72794000
CY2022Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	5767000
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-353784000
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1755391000
CY2021Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	2039514000
CY2021Q2	roiv	Issuance Of Subsidiary Warrants IssuanceOfSubsidiaryWarrants	2075000
CY2021Q2	roiv	Capital Contributions To Subsidiaries CapitalContributionsToSubsidiaries	0
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	19269000
CY2021Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-2439000
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-101078000
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1957341000
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-353784000
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-101078000
CY2022Q2	us-gaap	Share Based Compensation ShareBasedCompensation	72794000
CY2021Q2	us-gaap	Share Based Compensation ShareBasedCompensation	19269000
CY2022Q2	us-gaap	Gain Loss On Investments GainLossOnInvestments	-24547000
CY2021Q2	us-gaap	Gain Loss On Investments GainLossOnInvestments	-8619000
CY2022Q2	roiv	Gain Loss On Fair Value Of Debt And Liability Instruments GainLossOnFairValueOfDebtAndLiabilityInstruments	-41213000
CY2021Q2	roiv	Gain Loss On Fair Value Of Debt And Liability Instruments GainLossOnFairValueOfDebtAndLiabilityInstruments	-4585000
CY2022Q2	roiv	Gain On Termination Of Equity Interest Options GainOnTerminationOfEquityInterestOptions	0
CY2021Q2	roiv	Gain On Termination Of Equity Interest Options GainOnTerminationOfEquityInterestOptions	61472000
CY2022Q2	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-11263000
CY2021Q2	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-838000
CY2022Q2	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-19451000
CY2021Q2	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-6343000
CY2022Q2	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-18177000
CY2021Q2	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-7340000
CY2022Q2	roiv	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-2304000
CY2021Q2	roiv	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-1957000
CY2022Q2	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-1730000
CY2021Q2	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-2141000
CY2022Q2	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	6453000
CY2021Q2	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-5850000
CY2022Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-252082000
CY2021Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-141170000
CY2022Q2	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7459000
CY2021Q2	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2339000
CY2022Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-7459000
CY2021Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2339000
CY2022Q2	roiv	Proceeds From Subsidiary Debt Financings Net ProceedsFromSubsidiaryDebtFinancingsNet	159899000
CY2021Q2	roiv	Proceeds From Subsidiary Debt Financings Net ProceedsFromSubsidiaryDebtFinancingsNet	36400000
CY2022Q2	roiv	Repayment Of Long Term Debt And Convertible Debt By Subsidiary RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary	7344000
CY2021Q2	roiv	Repayment Of Long Term Debt And Convertible Debt By Subsidiary RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary	21590000
CY2022Q2	roiv	Payment For Offering And Loan Costs PaymentForOfferingAndLoanCosts	2250000
CY2021Q2	roiv	Payment For Offering And Loan Costs PaymentForOfferingAndLoanCosts	4600000
CY2022Q2	us-gaap	Payments For Repurchase Of Equity PaymentsForRepurchaseOfEquity	8329000
CY2021Q2	us-gaap	Payments For Repurchase Of Equity PaymentsForRepurchaseOfEquity	0
CY2022Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	141976000
CY2021Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10210000
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-117565000
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-133299000
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2074034000
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2141676000
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1956469000
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2008377000
CY2022Q2	roiv	Offering Costs Included In Accounts Payable And Accrued Expenses OfferingCostsIncludedInAccountsPayableAndAccruedExpenses	0
CY2021Q2	roiv	Offering Costs Included In Accounts Payable And Accrued Expenses OfferingCostsIncludedInAccountsPayableAndAccruedExpenses	4999000
CY2022Q2	roiv	Intangible Assets Recorded In Accounts Payable IntangibleAssetsRecordedInAccountsPayable	146172000
CY2021Q2	roiv	Intangible Assets Recorded In Accounts Payable IntangibleAssetsRecordedInAccountsPayable	0
CY2022Q2	roiv	Other Non Cash Transactions OtherNonCashTransactions	691000
CY2021Q2	roiv	Other Non Cash Transactions OtherNonCashTransactions	6654000
CY2022Q2	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1900000000
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-3100000000
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-353800000
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-101100000
CY2022Q2	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family: "Times New Roman"; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(B) Use of Estimates </div></div></div> <div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company regularly evaluates estimates and assumptions related to assets, liabilities, costs, expenses, contingent liabilities, share-based compensation and research and development costs. The Company bases its estimates and assumptions on historical experience and on various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.</div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">Additionally</div></div>, the Company assessed the impact that the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic has had on its operations and financial results as of June 30, 2022 and through the issuance of these condensed consolidated financial statements. The Company’s analysis was informed by the facts and circumstances as they were known to the Company. This assessment considered the impact <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> may have on financial estimates and assumptions <div style="letter-spacing: 0px; top: 0px;;display:inline;">that </div>affect the reported amounts of assets and liabilities and expenses. </div>
CY2022Q2	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family: "Times New Roman"; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(C) Concentrations </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to concentration of credit risk include cash and cash equivalents. The Company maintains cash deposits and cash equivalents in highly-rated, federally-insured financial institutions in excess of federally insured limits. The Company has established guidelines relative to diversification and maturities to maintain safety and liquidity. The Company has not experienced any credit losses related to these financial instruments and does not believe that it is exposed to any significant credit risk related to these instruments.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has long-lived assets in different geographic locations. As of June 30, 2022 and March 31, 2022, a majority of the Company’s long-lived assets were located in the United States.</div></div>
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1942215000
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2060400000
CY2022Q2	us-gaap	Restricted Cash RestrictedCash	14254000
CY2022Q1	us-gaap	Restricted Cash RestrictedCash	13634000
CY2022Q2	roiv	Cash And Cash Equivalents And Restricted Cash CashAndCashEquivalentsAndRestrictedCash	1956469000
CY2022Q1	roiv	Cash And Cash Equivalents And Restricted Cash CashAndCashEquivalentsAndRestrictedCash	2074034000
CY2022Q2	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P16Y6M
CY2022Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	146172000
CY2022Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	742000
CY2022Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	145430000
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	6700000
CY2025Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	8900000
CY2026Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	8900000
CY2027Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	8900000
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	8900000
CY2028Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	103100000
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	109354000
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	127531000
CY2021Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	1199072
CY2022Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.011
CY2021Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.001
CY2022Q2	roiv	Earn Out Shares Vested EarnOutSharesVested	0
CY2022Q2	roiv	Common Stock Warrants CommonStockWarrants	60021
CY2022Q2	us-gaap	Interest Income Other InterestIncomeOther	1981000
CY2021Q2	us-gaap	Interest Income Other InterestIncomeOther	71000
CY2022Q2	us-gaap	Interest Expense InterestExpense	2612000
CY2021Q2	us-gaap	Interest Expense InterestExpense	2513000
CY2022Q2	roiv	Other Income Expense OtherIncomeExpense	-1085000
CY2021Q2	roiv	Other Income Expense OtherIncomeExpense	2576000
CY2022Q2	roiv	Other Operating Income Expenses Net OtherOperatingIncomeExpensesNet	1716000
CY2021Q2	roiv	Other Operating Income Expenses Net OtherOperatingIncomeExpensesNet	-134000

Files In Submission

Name	View Source	Status
0001193125-22-220561-index-headers.html	Edgar Link	pending
0001193125-22-220561-index.html	Edgar Link	pending
0001193125-22-220561.txt	Edgar Link	pending
0001193125-22-220561-xbrl.zip	Edgar Link	pending
d383218d10q.htm	Edgar Link	pending
d383218dex311.htm	Edgar Link	pending
d383218dex312.htm	Edgar Link	pending
d383218dex321.htm	Edgar Link	pending
d383218dex322.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
roiv-20220630.xsd	Edgar Link	pending
Show.js	Edgar Link	pending
roiv-20220630_cal.xml	Edgar Link	unprocessable
roiv-20220630_lab.xml	Edgar Link	unprocessable
roiv-20220630_pre.xml	Edgar Link	unprocessable
d383218d10q_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable
roiv-20220630_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ROIV
Roivant Sciences Ltd. Stock $roiv

2022 Q3 Form 10-Q Financial Statement

#000119312522220561 Filed on August 15, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ROIV Roivant Sciences Ltd. Stock $roiv

2022 Q3 Form 10-Q Financial Statement

#000119312522220561 Filed on August 15, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ROIV
Roivant Sciences Ltd. Stock $roiv